1. Home
  2. CRWD vs VRTX Comparison

CRWD vs VRTX Comparison

Compare CRWD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CrowdStrike Holdings Inc.

CRWD

CrowdStrike Holdings Inc.

HOLD

Current Price

$390.39

Market Cap

118.2B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$476.81

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRWD
VRTX
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
118.2B
115.7B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
CRWD
VRTX
Price
$390.39
$476.81
Analyst Decision
Buy
Buy
Analyst Count
44
27
Target Price
$546.37
$526.79
AVG Volume (30 Days)
2.9M
1.4M
Earning Date
03-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
$3,953,624,000.00
$2,488,652,000.00
Revenue This Year
$23.94
$11.10
Revenue Next Year
$22.02
$10.23
P/E Ratio
N/A
$30.60
Revenue Growth
29.39
46.20
52 Week Low
$298.14
$362.50
52 Week High
$566.90
$519.68

Technical Indicators

Market Signals
Indicator
CRWD
VRTX
Relative Strength Index (RSI) 49.00 52.45
Support Level $400.02 $463.00
Resistance Level $432.85 $503.88
Average True Range (ATR) 20.00 14.23
MACD 3.06 -0.45
Stochastic Oscillator 77.81 35.21

Price Performance

Historical Comparison
CRWD
VRTX

About CRWD CrowdStrike Holdings Inc.

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: